HK1107148A1 - Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit - Google Patents

Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit

Info

Publication number
HK1107148A1
HK1107148A1 HK07112691.0A HK07112691A HK1107148A1 HK 1107148 A1 HK1107148 A1 HK 1107148A1 HK 07112691 A HK07112691 A HK 07112691A HK 1107148 A1 HK1107148 A1 HK 1107148A1
Authority
HK
Hong Kong
Prior art keywords
robo1
antibody
disclosed
medicament
manufacturing
Prior art date
Application number
HK07112691.0A
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Yoshitaka Hippo
Akira Watanabe
Masashi Fukayama
Yukio Ito
Masahiro Arai
Hirotaka Ito
Toshihiko Ohtomo
Shin-Ichi Funahashi
Yasuko Kinoshita
Original Assignee
Chugai Pharmaceutical Co Ltd
Hiroyuki Aburatani
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Hiroyuki Aburatani, Perseus Proteomics Inc filed Critical Chugai Pharmaceutical Co Ltd
Publication of HK1107148A1 publication Critical patent/HK1107148A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK07112691.0A 2004-03-31 2007-11-21 Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit HK1107148A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004102862 2004-03-31
JP2004227899 2004-08-04
JP2005004024 2005-01-11
PCT/JP2005/006838 WO2005095981A1 (ja) 2004-03-31 2005-03-31 抗robo1抗体を用いる癌の診断および治療

Publications (1)

Publication Number Publication Date
HK1107148A1 true HK1107148A1 (en) 2008-03-28

Family

ID=35063913

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112691.0A HK1107148A1 (en) 2004-03-31 2007-11-21 Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit

Country Status (11)

Country Link
US (1) US9644029B2 (ko)
EP (2) EP2226636B1 (ko)
JP (2) JP4913590B2 (ko)
KR (1) KR101300544B1 (ko)
CN (1) CN101014860B (ko)
AT (2) ATE476661T1 (ko)
AU (1) AU2005227598B2 (ko)
CA (1) CA2565175C (ko)
DE (1) DE602005022693D1 (ko)
HK (1) HK1107148A1 (ko)
WO (1) WO2005095981A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
KR20130132880A (ko) * 2010-12-23 2013-12-05 사노피 간암의 치료에 사용하기 위한 ｒｏｂｏ１－ｆｃ 융합 단백질
JP6078225B2 (ja) * 2011-09-29 2017-02-08 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を有効成分として含む肺癌治療剤
JP2015062367A (ja) * 2013-09-25 2015-04-09 国立大学法人 東京大学 Ｒｏｂｏ１タンパク質に対するダイアボディ型二重特異性抗体
KR101897322B1 (ko) * 2015-01-21 2018-09-10 재단법인 아산사회복지재단 원발성 갑상선암 전이의 진단방법 및 이를 이용한 진단키트
CN104873986A (zh) * 2015-03-23 2015-09-02 广东药学院 一种治疗肝脏纤维化的siRNA及其应用
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
WO2018208122A1 (ko) * 2017-05-12 2018-11-15 주식회사 온코태그디아그노스틱 담도 세포에서 메티오닐-타알엔에이 합성효소를 이용한 담도암 진단 방법
BR112021021092A2 (pt) * 2019-04-23 2023-02-28 Univ California Composições e métodos úteis na promoção de produção de leite

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287590A1 (en) 1997-04-18 1998-10-29 Millennium Biotherapeutics, Inc. Novel molecules of the fthma-070-related protein family and the t85-related protein family and uses thereof
DE69816467T2 (de) 1997-10-20 2004-04-15 The Regents Of The University Of California, Oakland Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
PL354093A1 (en) 1999-06-30 2003-12-29 Corixa Corporationcorixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2596901A (en) 1999-12-21 2001-07-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU3483001A (en) 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001092581A2 (en) 2000-05-26 2001-12-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002004514A2 (en) 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004512029A (ja) 2000-08-16 2004-04-22 カイロン　コーポレイション ヒト遺伝子および遺伝子発現産物
EP1432821A2 (en) * 2001-10-02 2004-06-30 Medical Research Council A method for the early detection of cancer
PT1572169E (pt) * 2002-03-08 2013-10-08 Shanghai Inst Biol Sciences Deteção e modulação da angiogénese mediada pela slit e roundabout (robo), e correspondentes utilizações
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
TWM325960U (en) * 2006-09-29 2008-01-21 Golden Point Marketing Ltd Folding control mechanism for baby stroller
CN201082718Y (zh) * 2007-07-19 2008-07-09 明门实业股份有限公司 婴儿车的单手收合致动机构

Also Published As

Publication number Publication date
ATE550661T1 (de) 2012-04-15
EP1744162A1 (en) 2007-01-17
US9644029B2 (en) 2017-05-09
CN101014860A (zh) 2007-08-08
ATE476661T1 (de) 2010-08-15
JPWO2005095981A1 (ja) 2008-02-21
JP4913590B2 (ja) 2012-04-11
AU2005227598A1 (en) 2005-10-13
KR101300544B1 (ko) 2013-09-02
CN101014860B (zh) 2012-01-25
KR20070018925A (ko) 2007-02-14
EP2226636A1 (en) 2010-09-08
CA2565175A1 (en) 2005-10-13
DE602005022693D1 (de) 2010-09-16
WO2005095981A1 (ja) 2005-10-13
US20150291694A1 (en) 2015-10-15
AU2005227598B2 (en) 2011-01-20
EP1744162B1 (en) 2010-08-04
EP1744162A4 (en) 2007-07-11
CA2565175C (en) 2017-12-19
JP4976562B2 (ja) 2012-07-18
EP2226636B1 (en) 2012-03-21
JP2011128161A (ja) 2011-06-30

Similar Documents

Publication Publication Date Title
HK1107148A1 (en) Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit
WO2006059245A3 (en) Compounds for the treatment of cns and amyloid associated diseases
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
MY153198A (en) Inhibitors of protein aggregation
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2005108949A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2007011606A3 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
ATE496021T1 (de) Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2006058014A3 (en) Harnessing network biology to improve drug discovery
DE602004014969D1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
WO2008144061A3 (en) Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
DE602006014691D1 (de) DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
EP2020445A4 (en) DETECTION OF INFLAMMATORY DISEASE AND COMPOSITION FOR PREVENTING OR TREATING AN INFLAMMATORY DISEASE
EA200870088A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2006110814A3 (en) Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
EA200701072A1 (ru) Препараты бензотиазола и их применение
WO2007013124A8 (en) Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target
DE602007011316D1 (de) Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180331